Abiomed to Present at Morgan Stanley Global Healthcare Unplugged Conference.DANVERS, Mass. -- Abiomed, Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : ABMD ABMD areal bone mineral density ABMD AEGIS Ballistic Missile Defense (US Navy) ABMD Advanced Ballistic Missile Defense ) announced today that Michael R. Minogue, Chairman, President and Chief Executive Officer, will present at the Morgan Stanley  To comply with Wikipedia's , the introduction of this article needs a complete rewrite. Global Healthcare Unplugged
Conference on May 3, 2007 at 9:30 a.m. ET. The conference will be held
at the Ritz-Carlton in Key Biscayne, Florida This article is about the village named Key Biscayne. For the island of the same name, see Key Biscayne. Key Biscayne is a village in Miami-Dade County, Florida, United States. The population was 10,507 at the 2000 census. . ABOUT ABIOMED Based in Danvers, Massachusetts Danvers is a town in Essex County, Massachusetts, United States. Located on the Danvers River near the northeastern coast of Massachusetts, Danvers is most widely known for its association with the 1692 Salem witch trials. , Abiomed, Inc., is a leading provider of medical devices that provide circulatory support to acute heart failure patients across the continuum of care in heart recovery. Our products are designed to enable the heart to rest, heal and recover by improving blood flow and/or performing the pumping of the heart. For additional information please visit: www.abiomed.com. FORWARD-LOOKING STATEMENTS This Release contains forward-looking statements, including statements regarding progress toward completion of clinical trials for Abiomed's products, including the Impella 2.5. The Company's actual results may differ materially from those anticipated in these forward-looking statements based upon a number of factors, including uncertainties associated with hospital and patient participation in trials, potentially conflicting results of future trials, the Company's ability to successfully obtain FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. approval of the Impella 2.5, development, testing and related regulatory approvals, complex manufacturing, high quality requirements, and other risks and challenges detailed in the Company's filings with the Securities and Exchange Commission, including its most recently filed quarterly report on Form 10-Q Form 10-Q See 10-Q. . Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this Release. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this Release or to reflect the occurrence of unanticipated events. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion